Endo International PLC (NASDAQ:ENDP) (TSE:ENL) was the recipient of some unusual options trading on Wednesday. Investors bought 11,595 put options on the stock. This represents an increase of 1,703% compared to the typical daily volume of 643 put options.
Several equities analysts have recently commented on ENDP shares. Zacks Investment Research upgraded Endo International from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a research report on Wednesday, January 9th. BidaskClub upgraded Endo International from a “hold” rating to a “buy” rating in a research report on Thursday, January 10th. ValuEngine upgraded Endo International from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. Piper Jaffray Companies reiterated a “hold” rating on shares of Endo International in a research report on Friday, March 1st. Finally, Leerink Swann lowered Endo International from an “outperform” rating to a “market perform” rating in a research report on Tuesday, March 5th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $15.44.
ENDP opened at $8.17 on Thursday. The company has a market capitalization of $1.85 billion, a PE ratio of 2.83 and a beta of 1.12. Endo International has a 52 week low of $5.64 and a 52 week high of $18.50.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, February 28th. The company reported $0.75 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.16. The company had revenue of $786.39 million during the quarter, compared to analysts’ expectations of $744.24 million. Endo International had a negative return on equity of 337.13% and a negative net margin of 35.00%. During the same quarter last year, the business posted $0.77 EPS. As a group, analysts expect that Endo International will post 2.19 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. LS Investment Advisors LLC bought a new position in Endo International during the 4th quarter valued at approximately $59,000. Oregon Public Employees Retirement Fund bought a new position in Endo International during the 4th quarter valued at approximately $76,000. First Quadrant L P CA bought a new position in Endo International during the 4th quarter valued at approximately $92,000. Signition LP bought a new position in Endo International during the 1st quarter valued at approximately $139,000. Finally, Neuburgh Advisers LLC increased its position in Endo International by 13.9% during the 4th quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after buying an additional 3,036 shares in the last quarter. Institutional investors own 95.03% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: Book Value Per Share in Stock Trading
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.